

tumour revealed *E. Coli*. He was treated with Meropenem for six weeks, and at follow-up, the patient was asymptomatic. Our scoping review illustrated that 18 meningioma-associated abscesses have been reported in the literature since the first report in 1994. Conclusions: This case highlights the hematogenous spread of a urinary infection, resulting in an intratumoural abscess. Review of the literature indicated that, similarly, 39% of cases had recent or concurrent urinary tract infections. Future studies should seek to determine conclusive guidelines for diagnosing intratumoural abscesses.

P.110

The use of 5-Aminolevulinic acid (5-ALA) in high-grade glioma surgery, a single Canadian center experience

*F Leblanc (Moncton) L Boone (St John's) T Noble (St John's) J Burns (Moncton) D Charest (Moncton) A El Helou (Moncton)**

doi: 10.1017/cjn.2023.200

Background: 5-Aminolevulinic acid (5-ALA) is a prodrug used to selectively illuminate high-grade glioma (HGG) tissue intra-operatively, shown to nearly double complete resection rates in a 2006 multicentre, phase III clinical trial. Here, we review the history of the 2020 approval of 5-ALA in Canada and present some of the first preliminary results on resection rates, survival analysis, and adverse effects from a single Canadian center. Methods: We enrolled 76 patients (median age 61 years, 42 male) with suspected HGG amenable to surgical resection between June 2020 and January 2023. Gross total resection was defined by the absence of enhancing lesions on postoperative MRI. We compared the survival distributions of confirmed HGG cases with complete vs. incomplete resection using a log-rank test and Kaplan-Meier statistic. Results: 52 patients were confirmed as having a HGG based on a pathological diagnosis. In 32 of these patients (60.3%) a gross total resection was achieved. 82.76% were still alive at 180 and 270 days, and 72.73% at 360 days. 47.8% had a survival of 600 or more days. Conclusions: 5-ALA fluorescence-guided surgery resulted in high complete resection rates, and improved overall survival comparable to the literature with no notable adverse side effects.

P.111

5-ALA guided surgical resection of newly diagnosed high grade gliomas at Health Sciences North (HSN) in Sudbury, Ontario

*L Roach (Sudbury) A Chown (Sudbury) S McGregor (Sudbury) A Wolf (Sudbury)**

doi: 10.1017/cjn.2023.201

Background: Since its approval by Health Canada in 2020, several neurosurgical centres across Canada have used 5-ALA, an oral drug that assists with surgical resection of malignant gliomas by causing tumour cells to fluoresce under the microscope. The study's objective is to prospectively evaluate the extent of resection (EOR) and clinical outcomes in 5-ALA-guided surgery at HSN compared to historical controls. Methods: A retrospective analysis was performed of patients with

malignant gliomas having undergone surgery at HSN from 2011 to December 2020, assessing the EOR (contrast-enhanced tumour on post-operative CT/MRI), progression-free survival (PFS), overall survival (OS). Results: 235 patients underwent surgery for malignant glioma including 51 newly-diagnosed patients felt to be surgically resectable and with post-operative imaging. 25/51 (49%) had no residual tumour. The median PFS and OS were 7.1 and 11.5 months respectively. To date, 3 patients have successfully undergone 5-ALA-guided surgery with complete resection of contrast-enhancing tumour and no new focal neurological deficit post-operatively. Conclusions: We continue to recruit and follow prospectively patients having undergone 5-ALA-guided resection of malignant gliomas at HSN. Patients living in Northern Ontario may derive significant benefits from the use of 5-ALA-guided surgery, particularly since other technologies, such as intraoperative MRI and ultrasound, are costly and not available.

P.112

Location pattern of recurrence of WHO Grade 1 Meningiomas

*K Ong (Vancouver) M Rizzuto (Vancouver) S Makarenko (Vancouver)**

doi: 10.1017/cjn.2023.202

Background: Meningiomas can lead to significant morbidity and mortality and have recurrence potential despite their benign classification. The precise location of the recurrence has not been delineated. The objective of this study was to determine any spatial clustering of recurrence for surgically treated Grade 1 meningiomas. Methods: Patients diagnosed with Grade 1 meningiomas and treated with surgical resection with recurrence were reviewed. Patient demographics, presentation, extent of resection, time to recurrence, and location were established by medical records. Outcomes were the time to recurrence and location relative to the original surgical bed. Results: Among the 42 cases that met the study inclusion criteria, 12 were male and 30 were female. The mean age at treatment was 49.7 years, and the mean years until recurrence was 5.2 years. 33 (68.8%) tumours recurred locally, 12 (25.0%) recurred at the periphery (<1cm of the surgical bed), and 3 (6.3%) recurred distal to the resection site. Conclusions: A sizeable portion of cases may benefit from therapy directed beyond the resection margin. It may be more successful to prevent recurrence in these patients by performing a more aggressive resection of the dural attachment surrounding the tumour and/or focusing adjuvant therapy on the area surrounding the resection cavity.

P.113

Impact of 5-ALA on rates of complete high grade glioma resection: a Canadian perspective

D Catana (Ottawa) J Malone (Ottawa) J Sinclair (Ottawa)*

doi: 10.1017/cjn.2023.203

Background: The relationship between glioblastoma extent of surgical resection (EoR) and survival is well documented.¹⁻³ The